“…For injection volumes >1 mL, there are concerns of increased pain upon injection, high subcutaneous back pressure, site leakage, and injection site reactions. [14][15][16][17][18][19][20][21] Studies investigating subcutaneous rehydration and subcutaneous immunoglobulin replacement therapy have shown that the subcutaneous tissue can accommodate volumes >1 mL with good tolerability. [22][23][24][25][26][27] Hizentra (CSL Behring, Kankakee, IL), Gammunex-C (Grifols Therapeutics, Research Triangle Park, NC), and Gammagard Liquid (Baxter, Westlake Village, CA) are commercially available immunoglobulin replacement products in the United States.…”